Gilead Sciences | World Briefings
Subscribe to World Briefings's newsletter

News Updates

Let's join our newsletter!

Do not worry we don't spam!

Gilead's Trodelvy: A Triplet Regimen Fails in First-Line Lung Cancer - What Does This Mean for the Future?

World

19 Sep, 2024

Gilead's Trodelvy: A Triplet Regimen Fails in First-Line Lung Cancer - What Does This Mean for the Future?


Gilead Sciences has been on the hunt for a win with its antibody-drug conjugate (ADC) Trodelvy after facing two surprising...

Newsletter
Subscribe to Newsletter

Stay Tuned With Updates